Foresight Diagnostics Reports Clinical Performance Data for ctDNA Assay in Early-Stage Lung Cancer
Study shows Foresight CLARITY demonstrated 68% pre-operative and 38% post-operative MRD detection rates in stage I lung cancer patients.
Read MorePosted by CLP Edit Staff | Sep 10, 2025 | Sequencing Systems |
Study shows Foresight CLARITY demonstrated 68% pre-operative and 38% post-operative MRD detection rates in stage I lung cancer patients.
Read MorePosted by Alyx Arnett | Sep 2, 2025 | Sepsis |
A recent poll highlights growing interest in host response testing for sepsis. Immunexpress CEO Rollie Carlson discusses the findings and the future of rapid diagnostics.
Read MorePosted by CLP Edit Staff | Aug 15, 2025 | Hematology & Serology |
The Oak Ridge, Tennessee-based company’s next-generation analyzer delivers results three times faster than its predecessor while maintaining laboratory-grade diagnostic precision.
Read MorePosted by Alyx Arnett | Jul 30, 2025 | Company News |
While functional medicine has long existed on the fringes of healthcare, Adam El-Hosseiny, COO of Access Medical Labs, believes it’s now moving into the mainstream.
Read MorePosted by Chris Wolski | Jul 24, 2025 | Hematology & Serology |
MeMed has unveiled MeMed BV Flex, a rapid fingerstick-based test that distinguishes bacterial from viral infections in 15 minutes.
Read More